136059-34-2

Upstream product

• 100-58-3 phenylmagnesium bromide 
• 5180-33-6 1,1-Diphenyl-propan-1-ol 
• 778-66-5 1,1-diphenyl-1-propene 
• 108-86-1 bromobenzene 
• 4801-15-4 3-bromo-1,1-diphenyl-1-propene 
• 107-21-1 ethylene glycol 

Downstream Products

• 1251854-04-2 C₂₁H₂₃NO₃ 
• 1251854-14-4 11-methyl-9,9-diphenyl-6,10-dioxa-3-azabicyclo[6.3.0]undec-1⁽¹¹⁾-en-2-one 
• 136059-33-1 2-(3,3-diphenyl-1-propyloxy)ethanol 

Relevant academic research and scientific papers

Manganese(III)-assisted specific intramolecular addition

Oligomethylene-tethered -alkenyl 3-oxobutanoates and 3-oxobutanamides underwent manganese(III)-mediated oxidative intramolecular addition to produce dihydrofuran-fused macrolides and macrocyclic amides from 8 to 26 members. A similar reaction of the oligooxamethylene-tethered -alkenyl 3-oxobutanoates also gave dihydrofuran-fused crown ether type macrolides which had a phase-transfer ability with sodium and potassium picrates. The manganese(III)-assisted specific intramolecular addition could be explained by the -complexation of the -alkenyl part with the manganese(III) enolate. Georg Thieme Verlag Stuttgart - New York.

Synthesis of macrocyclic amides using manganese(III)-based intramolecular cyclization of N-(ω-Alkenyl)-3-oxobutanamides

The reaction of N-(ω-alkenyl)-3-oxobutanamides with manganese(III) acetate in glacial acetic acid at reflux temperature under an argon atmosphere resulted in the oxidative intramolecular radical cyclization that produced bicyclomacrocyclic amides in moder

Method of treating filariae

The present invention relates to a novel method for treating a mammal suffering from filariae.

Synthesis of novel GABA uptake inhibitors. 4. Bioisosteric transformation and successive optimization of known GABA uptake inhibitors leading to a series of potent anticonvulsant drug candidates

By bioisosteric transformations and successive optimization of known GABA uptake inhibitors, several series of novel GABA uptake inhibitors have been prepared by different synthetic approaches. These compounds are derivatives of nipecotic acid and guvacine, substituted at the nitrogen of these amino acids by various lipophilic moieties such as diarylaminoalkoxyalkyl or diarylalkoxyalkyl. The in vitro values for inhibition of [3H]GABA uptake in rat synaptosomes was determined for each compound, and it was found that the most potent compound from this series, (R)-1-(2-(3,3-diphenyl-1-propyloxy)ethyl)-3-piperidinecarboxylic acid hydrochloride (29), is so far the most potent parent compound inhibiting GABA uptake into synaptosomes. Structure-activity results confirm our earlier observations, that an electronegative center in the chain connecting the amino acid and diaryl moiety is very critical in order to obtain high in vitro potency. Several of the novel compounds were also evaluated for their ability in vivo to inhibit clonic seizures induced by a 15 mg/kg (ip) dose of methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate (DMCM). Some of the compounds tested show a high in vivo potency comparable with that of the recently launched anticonvulsant product 6 ((R)-1-(4,4-bis(3-methyl-2- thienyl)-3-butenyl)-3-piperidinecarboxylic acid).

Heterocyclic carboxylic acids

Novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent, the compounds thus having the general formula I STR1 wherein Y is STR2 wherein R1 and R2 independently are C3-8 cycloalkyl phenyl or thienyl all of which may be optionally substituted with halogen, trifluoromethyl, C1-16 alkyl or C1-6 alkoxy; s is 1, 2 or 3; x is --CH2 --, --O-- or STR3 -wherein R3 is hydrogen or C1-6 -alkyl; r is 2, 3 or 4; R4 and R5 each represents hydrogen or may together represent a bond and R6 is OH or C1-8 -alkoxy; and pharmaceutically acceptable acid addition salts are potent inhibitors of GABA uptake from the synaptic cleft.